Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Kreer C, et al. Among authors: krahling v. Cell. 2020 Sep 17;182(6):1663-1673. doi: 10.1016/j.cell.2020.08.046. Cell. 2020. PMID: 32946786 Free PMC article. No abstract available.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F. Ehrhardt SA, et al. Among authors: krahling v. Nat Med. 2019 Oct;25(10):1589-1600. doi: 10.1038/s41591-019-0602-4. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591605 Clinical Trial.
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Kreer C, et al. Among authors: krahling v. Cell. 2020 Aug 20;182(4):843-854.e12. doi: 10.1016/j.cell.2020.06.044. Epub 2020 Jul 13. Cell. 2020. PMID: 32673567 Free PMC article.
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.
Krähling V, Halwe S, Rohde C, Becker D, Berghöfer S, Dahlke C, Eickmann M, Ercanoglu MS, Gieselmann L, Herwig A, Kupke A, Müller H, Neubauer-Rädel P, Klein F, Keller C, Becker S. Krähling V, et al. J Immunol Methods. 2021 Mar;490:112958. doi: 10.1016/j.jim.2021.112958. Epub 2021 Jan 4. J Immunol Methods. 2021. PMID: 33412174 Free PMC article.
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M, Rohde C, Krähling V, Gellhorn Serra M, Kreer C, Klüver M, Sauerhering L, Schmidt J, Cai Z, Han F, Young D, Yang G, Widera M, Koch M, Werner A, Kämper L, Becker N, Marlow MS, Eickmann M, Ciesek S, Schiele F, Klein F, Becker S. Halwe S, et al. Among authors: krahling v. Viruses. 2021 Jul 29;13(8):1498. doi: 10.3390/v13081498. Viruses. 2021. PMID: 34452363 Free PMC article.
Ebola Virus Activates IRE1α-Dependent XBP1u Splicing.
Rohde C, Pfeiffer S, Baumgart S, Becker S, Krähling V. Rohde C, et al. Among authors: krahling v. Viruses. 2022 Dec 30;15(1):122. doi: 10.3390/v15010122. Viruses. 2022. PMID: 36680162 Free PMC article.
Serine-Arginine Protein Kinase 1 Regulates Ebola Virus Transcription.
Takamatsu Y, Krähling V, Kolesnikova L, Halwe S, Lier C, Baumeister S, Noda T, Biedenkopf N, Becker S. Takamatsu Y, et al. Among authors: krahling v. mBio. 2020 Feb 25;11(1):e02565-19. doi: 10.1128/mBio.02565-19. mBio. 2020. PMID: 32098814 Free PMC article.
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM. Koch T, et al. Among authors: krahling v. Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21. Lancet Infect Dis. 2020. PMID: 32325037 Free PMC article. Clinical Trial.
53 results